0001104659-24-027198.txt : 20240226 0001104659-24-027198.hdr.sgml : 20240226 20240226060401 ACCESSION NUMBER: 0001104659-24-027198 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240226 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Astrana Health, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 24673447 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: Apollo Medical Holdings, Inc. DATE OF NAME CHANGE: 20080715 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 tm247084d1_8k.htm FORM 8-K
false --12-31 0001083446 0001083446 2024-02-26 2024-02-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 26, 2024

 

ASTRANA HEALTH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware 001-37392 95-4472349
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

 

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

 

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

 

Apollo Medical Holdings, Inc.

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ASTH The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

 

 

   

 

 

Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

As previously announced, on January 25, 2024, Astrana Health, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a change in corporate name from “Apollo Medical Holdings, Inc.” to “Astrana Health, Inc.” (the “Name Change”). The Name Change became effective as of 12:01 a.m. Eastern Time on February 26, 2024.

 

In connection with the Name Change, effective February 26, 2024, the Company’s By-Laws were amended and restated to reflect the Name Change and incorporate all prior amendments to the By-Laws. No other changes were made to the By-Laws. A copy of the Amended and Restated By-Laws is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

In connection with the Name Change, the Company’s common stock began trading on The Nasdaq Stock Market LLC under the new ticker symbol “ASTH” on February 26, 2024.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
3.1   Amended and Restated By-Laws (effective February 26, 2024).
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ASTRANA HEALTH, INC.
   
Date: February 26, 2024 By: /s/ Brandon Sim
  Name: Brandon Sim
  Title: Chief Executive Officer and President

 

 

 EX-3.1 2 tm247084d1_ex3-1.htm EXHIBIT 3.1

Exhibit 3.1

 

ASTRANA HEALTH, INC.

 

AMENDED AND RESTATED BY-LAWS

 

Amended and restated as of February 26, 2024

 

 

 

 

TABLE OF CONTENTS

 

ARTICLE I - OFFICES 1
Section 1.1 - Principal Office 1
Section 1.2 - Other Offices 1
   
ARTICLE II - SHAREHOLDERS 1
Section 2.1 - Annual Meeting 1
Section 2.2 - Special Meetings 1
Section 2.3 - Notice of Meetings 1
Section 2.4 - Quorum 1
Section 2.5 - Organization 2
Section 2.6 - Conduct of Business 2
Section 2.7 - Proxies and Voting 2
Section 2.8 - Shareholder Action By Written Consent 2
Section 2.9 - Stock List 3
Section 2.10 - Meetings by Telecommunication 3
   
ARTICLE III - BOARD OF DIRECTORS 3
Section 3.1 - Number and Term of Office 3
Section 3.2 - Vacancies 3
Section 3.3 - Regular Meetings 4
Section 3.4 - Special Meetings 4
Section 3.5 - Quorum 4
Section 3.6 - Participation in Meetings by Conference Telephone 4
Section 3.7 - Conduct of Business 4
Section 3.8 - Powers 5
Section 3.9 - Compensation of Directors 5
Section 3.10 - Interested Directors 5
Section 3.11 - Loans 6
   
ARTICLE IV - COMMITTEES 6
Section 4.1 - Committees of the Board of Directors 6
Section 4.2 - Conduct of Business 6
   
ARTICLE V - OFFICERS 7
Section 5.1 - Generally 7
Section 5.2 - President 7
Section 5.3 - Vice-president 7
Section 5.4 - Treasurer 7
Section 5.5 - Secretary 7
Section 5.6 - General Manager 7
Section 5.7 - Delegation of Authority 8
Section 5.8 - Removal 8
Section 5.9 - Action with Respect to Securities of Other Corporation 8

 

 

 

 

   
ARTICLE VI - INDEMNIFICATION OF DIRECTORS, OFFICERS AND OTHERS 8
Section 6.1 - Generally 8
Section 6.2 - Expenses 9
Section 6.3 - Determination by Board of Directors 9
Section 6.4 - Non-exclusive Right 9
Section 6.5 - Insurance 9
Section 6.6 - Violation of Law 10
Section 6.7 - Coverage 10
   
ARTICLE VII - STOCK 10
Section 7.1 - Certificates of Stock 10
Section 7.2 - Transfers of Stock 10
Section 7.3 - Record Date 11
Section 7.4 - Lost, Stolen or Destroyed Certificates 11
Section 7.5 - Regulations 11
   
ARTICLE VIII - NOTICES 11
Section 8.1 - Notices 11
Section 8.2 - Waivers 11
   
ARTICLE IX - MISCELLANEOUS 11
Section 9.1 - Facsimile Signatures 11
Section 9.2 - Corporate Seal 11
Section 9.3 - Reliance upon Books, Reports and Records 12
Section 9.4 - Fiscal Year 12
Section 9.5 - Time Periods 12
   
ARTICLE X - AMENDMENTS 12
Section 10.1 - Amendments 12

 

 

 

 

ARTICLE I - OFFICES

 

Section 1.1 - Principal Office

 

The principal executive office of the corporation shall be such location as deemed necessary from time to time by the Board of Directors.

 

Section 1.2 - Other Offices

 

The corporation may also have such other offices, either within or without the State of Delaware, as the Board of Directors may from time to time determine or the business of the corporation may require.

 

ARTICLE II - SHAREHOLDERS

 

Section 2.1 - Annual Meeting

 

An annual meeting of the shareholders, for the selection of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors shall fix. If the Board of Directors does not designate a location for the annual meeting of the shareholders, such meeting shall be held at the principal executive offices of the Corporation.

 

Section 2.2 - Special Meetings

 

Special meetings of the shareholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by the Board of Directors, the president, the chief executive officer, or the holders of not less than one-tenth of all the shares entitled to vote at the meeting, and shall be held at such place, on such date, and at such time as they or he shall fix.

 

Section 2.3 - Notice of Meetings

 

Written notice of the place, date and time of all meetings of the shareholders shall be given, not less than ten nor more than sixty days before the date on which the meeting is to be held, to each stockholder entitled to vote at such meeting, except as otherwise provided herein or required by law (meaning, here and hereinafter, as required from time to time by the corporation statutes of the State of Delaware).

 

When a meeting is adjourned to another place, date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the meeting at which the adjournment is taken; provided, however, that if the date of any adjourned meeting is more than thirty days after the date for which the meeting was originally noticed, or if a new record date is fixed for the adjourned meeting, written notice of the place, date, and time of the adjourned meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting.

 

Section 2.4 - Quorum

 

At any meeting of the shareholders, the holders of a majority of all of the shares of the stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes, unless or except to the extent that the presence of a larger number may be required by law.

 

1

 

 

If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of the stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, date or time.

 

If a notice of any adjourned special meeting of shareholders is sent to all shareholders entitled to vote thereat, stating that it will be held with those present constituting a quorum, then except as otherwise required by law, those present at such adjourned meeting shall constitute a quorum, and all matters shall be determined by a majority of the votes cast at such meeting.

 

Section 2.5 - Organization

 

Such person as the Board of Directors may have designated or, in the absence of such a person, the highest ranking officer of the corporation who is present shall call to order any meeting of the shareholders and act as chairman of the meeting. In the absence of the Secretary of the corporation, the secretary of the meeting shall be the person the chairman appoints.

 

Section 2.6 - Conduct of Business

 

The chairman of any meeting of shareholders shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seem to him in order.

 

Section 2.7 - Proxies and Voting

 

At any meeting of the shareholders, every shareholder entitled to vote may vote in person or by proxy authorized by an instrument in writing filed in accordance with the procedure established for the meeting.

 

Each shareholder shall have one vote for every share of stock entitled to vote which is registered in his name on the record date for the meeting, except as otherwise provided herein or required by law.

 

All voting, except on the election of directors and where otherwise required by law, may be by a voice vote; provided, however, that upon demand therefor by a shareholder entitled to vote or his proxy, a stock vote shall be taken. Every stock vote shall be taken by ballots, each of which shall state the name of the shareholder or proxy voting and such other information as may be required under the procedure established for the meeting. Every vote taken by ballots shall be counted by an inspector or inspectors appointed by the chairman of the meeting.

 

If a quorum is present, all matters shall be determined by a majority of the votes cast affirmatively or negatively, unless a greater number or voting by class is required by law, the Certificate of Incorporation of the Corporation or these By-laws. Notwithstanding the preceding sentence and anything in the last paragraph of Section 2.4 to the contrary, all director elections shall be determined by a plurality of the votes cast.

 

Section 2.8 - Shareholder Action By Written Consent

 

Any action which may be taken at a meeting of the Shareholders may be taken by written consent without a meeting if such action is taken in conformance with the Delaware Corporations Code.

 

2

 

 

Section 2.9 - Stock List

 

A complete list of shareholders entitled to vote at any meeting of shareholders, arranged in alphabetical order for each class of stock and showing the address of each such shareholder and the number of shares registered in his name, shall be open to the examination of any such shareholder, for any purpose germane to the meeting, during ordinary business hours for a period of at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or if not so specified, at the place where the meeting is to be held.

 

The Stock list shall also be kept at the place of the meeting during the whole time thereof and shall be open to the examination of any such shareholder who is present. This list shall presumptively determine the identity of the shareholders entitled to vote at the meeting and the number of shares held by each of them.

 

Section 2.10 - Meetings by Telecommunication

 

Any meeting of the shareholders may be conducted through the use of any means of communication which allows persons participating in the meeting to hear one another.

 

ARTICLE III - BOARD OF DIRECTORS

 

Section 3.1 - Number and Term of Office

 

The authorized number of directors shall be fixed from time to time by the Board of Directors, provided that the authorized number of directors shall not be less than one (1).

 

The term of office of each director elected or appointed at or after the 2018 annual meeting of stockholders of the Corporation shall expire at the next annual meeting of stockholders following the date of election or appointment; provided, however, the term of any director who was elected or appointed prior to the 2018 annual meeting of stockholders will not be shortened. Each director shall serve until his or her successor is duly elected and qualified or until his or her death, resignation or removal.

 

As a result, (i) the terms of the Class I directors shall expire at the Company’s 2018 annual meeting of stockholders, and concurrently therewith, Class I shall be eliminated, (ii) the terms of the Class II directors shall expire at the Company’s 2019 annual meeting of stockholders, and concurrently therewith, Class II shall be eliminated, and (iii) the terms of the Class III directors shall expire at the Company’s 2020 annual meeting of stockholders, and concurrently therewith, Class III shall be eliminated.

 

Any decrease in the authorized number of directors shall not become effective until the expiration of the term of the directors then in office unless, at the time of such decrease, there shall be vacancies on the board which are being eliminated by the decrease. No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration of the director’s term of office.

 

Section 3.2 - Vacancies

 

Subject to the rights of the holders of any series of Preferred Stock then outstanding, newly created directorships resulting from any increase in the authorized number of directors or any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall, unless otherwise required by law or by resolution of the Board of Directors, be filled only by a majority vote of the directors then in office, even if less than a quorum (and not by the stockholders), and directors so chosen shall serve for a term expiring at the next annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified. No decrease in the number of authorized directors shall shorten the term of any incumbent director.

 

3

 

 

Subject to the rights of the holders of any series of Preferred Stock then outstanding, any director, or the entire Board of Directors, may be removed from office at any time, either for or without cause, but only by the affirmative vote of the holders of a majority in voting power of the shares then entitled to vote thereon, voting together as a single class.

 

Section 3.3 - Regular Meetings

 

Regular meetings of the Board of Directors shall be held at such place or places, on such date or dates, and at such time or times as shall have been established by the Board of Directors and publicized among all directors. A notice of each regular meeting shall not be required.

 

Section 3.4 - Special Meetings

 

Special meetings of the Board of Directors may be called by one-third of the directors then in office or by the chief executive officer and shall be held at such place, on such date and at such time as they or he shall fix. Notice of the place, date and time of each such special meeting shall be given by each director by whom it is not waived by mailing written notice not less than three days before the meeting or by telegraphing the same not less than eighteen hours before the meeting. Unless otherwise indicated in the notice thereof, any and all business may be transacted at a special meeting.

 

Section 3.5 - Quorum

 

At any meeting of the Board of Directors, a majority of the total number of the whole board shall constitute a quorum for all purposes. If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date or time, without further notice or waiver thereof.

 

Section 3.6 - Participation in Meetings by Conference Telephone

 

Members of the Board of Directors or of any committee thereof, may participate in a meeting of such board or committee by means of conference telephone or similar communications equipment that enables all persons participating in the meeting to hear each other. Such participation shall constitute presence in person at such meeting.

 

Section 3.7 - Conduct of Business

 

At any meeting of the Board of Directors, business shall be transacted in such order and manner as the board may from time to time determine, and all matters shall be determined by the vote of a majority of the directors present, except as otherwise provided herein or required by law. Action may be taken by the Board of Directors without a meeting if all members thereof consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors.

 

4

 

 

Section 3.8 - Powers

 

The Board of Directors may, except as otherwise required by law, exercise all such powers and do all such acts and things as may be exercised or done by the corporation, including, without limiting the generality of the foregoing, the unqualified power:

 

  (a) To declare dividends from time to time in accordance with law;

 

(b)To purchase or otherwise acquire any property, rights or privileges on such terms as it shall determine;

 

(c)To authorize the creation, making and issuance, in such form as it may determine, of written obligations of every kind, negotiable or non-negotiable, secured or unsecured, and to do all things necessary in connection therewith;

 

(d)To remove any officer of the corporation with or without cause, and from time to time to devolve the powers and duties of any officer upon any other person for the time being;

 

(e)To confer upon any officer of the corporation the power to appoint, remove and suspend subordinate officers and agents;

 

(f)To adopt from time to time such stock option, stock purchase, bonus or other compensation plans for directors, officers and agents of the corporation and its subsidiaries as it may determine;

 

(g)To adopt from time to time such insurance, retirement and other benefit plans for directors, officers and agents of the corporation and its subsidiaries as it may determine; and

 

(h)To adopt from time to time regulations, not inconsistent with these By-laws, for the management of the corporation’s business and affairs.

 

Section 3.9 - Compensation of Directors

 

Directors, as such, may receive, pursuant to resolution of the Board of Directors, fixed fees and other compensation for their services as directors, including, without limitation, their services as members of committees of the directors.

 

Section 3.10 - Interested Directors

 

(a)No contract or transaction between the corporation and one or more of its directors or officers, or between the corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers, are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose, if;

 

(1)The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or

 

5

 

 

(2)The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the shareholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the shareholders; or

 

(3)The contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee or the shareholders.

 

(b)Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction.

 

Section 3.11 - Loans

 

The corporation shall not lend money to or use its credit to assist its officers, directors or other control persons without authorization in the particular case by the shareholders, but may lend money to and use its credit to assist any employee, excluding such officers, directors or other control persons of the corporation or of a subsidiary, if such loan or assistance benefits the corporation.

 

ARTICLE IV - COMMITTEES

 

Section 4.1 - Committees of the Board of Directors

 

The Board of Directors, by a vote of a majority of the whole board, may from time to time designate committees of the board, with such lawfully powers and duties as it thereby confers, to serve at the pleasure of the board and shall, for those committees and any others provided for herein, elect a director or directors to serve as the member or members, designating, if it desires, other directors as alternative members who may replace any absent or disqualified member at any meeting of the committee. Any committee so designated may exercise the power and authority of the Board of Directors to declare a dividend or to authorize the issuance of stock if the resolution which designates the committee or a supplemental resolution of the Board of Directors shall so provide. In the absence or disqualification of any member of any committee and any alternate member in his place, the member or members of the committee present at the meeting and not disqualified from voting, whether or not he or they constitute a quorum, may by unanimous vote appoint another member of the Board of Directors to act at the meeting in the place of the absent or disqualified member.

 

Section 4.2 - Conduct of Business

 

Each committee may determine the procedural rules for meeting and conducting its business and shall act in accordance therewith, except as otherwise provided herein or required by law. Adequate provisions shall be made for notice to members of all meetings; a majority of the members shall constitute a quorum unless the committee shall consist of one or two members, in which event one member shall constitute a quorum; and all matters shall be determined by a majority vote of the members present. Action may be taken by any committee without a meeting if all members thereof consent thereto in writing, and the writing or writings are filed with the minutes of the proceedings of such committee.

 

6

 

 

ARTICLE V - OFFICERS

 

Section 5.1 - Generally

 

The officers of the corporation shall consist of a president, one or more vice-presidents, a secretary, a treasurer and such other subordinate officers as may from time to time be appointed by the Board of Directors. Officers shall be elected by the Board of Directors, which shall consider that subject at its first meeting after every annual meeting of shareholders. Each officer shall hold his office until his successor is elected and qualified or until his earlier resignation or removal. Any number of offices may be held by the same person.

 

Section 5.2 - President

 

The President shall be the chief executive officer of the corporation, except as set forth in Section 5.6 of this Article. Subject to the provisions of these By-laws and to the direction of the Board of Directors, he shall have the responsibility for the general management and control of the affairs and business of the corporation and shall perform all duties and have all powers which are commonly incident to the office of chief executive or which are delegated to him by the Board of Directors. He shall have power to sign all stock certificates, contracts and other instruments of the corporation which are authorized. He shall have general supervision and direction of all of the other officers and agents of the corporation.

 

Section 5.3 - Vice-president

 

Each vice-president shall perform such duties as the Board of Directors shall prescribe. In the absence or disability of the President, the vice-president who has served in such capacity for the longest time shall perform the duties and exercise the powers of the President.

 

Section 5.4 - Treasurer

 

The treasurer shall have the custody of the monies and securities of the corporation and shall keep regular books of account. He shall make such disbursements of the funds of the corporation as are proper and shall render from time to time an account of all such transactions and of the financial condition of the corporation.

 

Section 5.5 - Secretary

 

The secretary shall issue all authorized notices for, and shall keep minutes of, all meetings of the shareholders and the Board of Directors and shall have charge of the corporate books.

 

Section 5.6 - General Manager

 

The Board of Directors may employ and appoint a general manager who may, or may not, be one of the officers or directors of the corporation. If employed by the Board of Directors he shall be the chief operating officer of the corporation and, subject to the directions of the Board of Directors, shall have general charge of the business operations of the corporation and general supervision over its employees and agents. He shall have the exclusive management of the business of the corporation and of all of its dealings, but at all times subject to the control of the Board of Directors. Subject to the approval of the Board of Directors or a committee, he shall employ all employees of the corporation, or delegate such employment to subordinate officers, or division officers, or division chiefs, and shall have authority to discharge any person so employed. He shall make a report to the President and directors quarterly, or more often if required to do so, setting forth the results of the operations under his charge, together with suggestions regarding the improvement and betterment of the condition of the corporation, and shall perform such other duties as the Board of Directors shall require.

 

7

 

 

Section 5.7 - Delegation of Authority

 

The Board of Directors may, from time to time, delegate the powers or duties of any officer to any other officers or agents, notwithstanding any provision hereof.

 

Section 5.8 - Removal

 

Any officer of the corporation may be removed at any time, with or without cause, by the Board of Directors.

 

Section 5.9 - Action with Respect to Securities of Other Corporation

 

Unless otherwise directed by the Board of Directors, the president shall have power to vote and otherwise act on behalf of the corporation, in person or by proxy, at any meeting of shareholders of or with respect to any action of shareholders of any other corporation in which this corporation may hold securities and otherwise to exercise any and all rights and powers which this corporation may possess by reason of its ownership of securities in such other corporation.

 

ARTICLE VI - INDEMNIFICATION OF DIRECTORS, OFFICERS AND OTHERS

 

Section 6.1 - Generally

 

The corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or items equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was lawful.

 

The corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorney’s fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable for negligence or misconduct in the performance of his duty to the corporation unless and only to the extent that the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

 

8

 

 

Section 6.2 - Expenses

 

To the extent that a director, officer, employee or agent of the corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 6.1 of this Article, or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorney’s fees) actually and reasonably incurred by him in connection therewith. Expenses incurred in defending a civil or criminal action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding as authorized in the manner provided in Section 6.3 of this Article upon receipt of an undertaking by or on behalf of the director, officer, employee or agent to repay such amount unless it shall ultimately be determined that he is entitled to be indemnified by the corporation as authorized in this Article.

 

Section 6.3 - Determination by Board of Directors

 

Any indemnification under Section 6.1 of this Article (unless ordered by a court) shall be made by the corporation only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances because he has met the applicable standard of conduct set forth in Section 6.1 of this Article. Such determination shall be made by the Board of Directors by a majority vote of a quorum of the directors, or by the shareholders.

 

Section 6.4 - Non-exclusive Right

 

The indemnification provided by this Article shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any by-law, agreement, vote of shareholders or interested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding such office and shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person.

 

Section 6.5 - Insurance

 

The corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity or arising out of his status as such, whether or not the corporation would have the power to indemnify him against such liability under the provisions of this Article.

 

The corporation’s indemnity of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall be reduced by any amounts such person may collect as indemnification (i) under any policy of insurance purchased and maintained on his behalf by the corporation or (ii) from such other corporation, partnership, joint venture, trust or other enterprise.

 

9

 

 

Section 6.6 - Violation of Law

 

Nothing contained in this Article, or elsewhere in these By-laws, shall operate to indemnify any director or officer if such indemnification is for any reason contrary to law, either as a matter of public policy, or under the provisions of the Federal Securities Act of 1933, the Securities Exchange Act of 1934, or any other applicable state or federal law.

 

Section 6.7 - Coverage

 

For the purposes of this Article, references to “the corporation” include all constituent corporations absorbed in a consolidation or merger as well as the resulting or surviving corporation so that any person who is or was a director, officer, employee or agent of such a constituent corporation or is or was serving at the request of such a constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise shall stand in the same position under the provisions of this Article with respect to the resulting or surviving corporation as he would if he had served the resulting or surviving corporation in the same capacity.

 

ARTICLE VII - STOCK

 

Section 7.1 - Certificates of Stock

 

The shares of stock of the corporation shall be represented by a certificate, unless and until the Board of Directors adopts a resolution permitting shares to be uncertificated. Notwithstanding the adoption of any such resolution providing for uncertificated shares, every holder of stock of the corporation theretofore represented by certificates and, upon request, every holder of uncertificated shares, shall be entitled to a certificate signed by, or in the name of the corporation by, the President or a vice-president, and by the secretary or an assistant secretary, or the treasurer or an assistant treasurer, certifying the number of shares owned by him. Any of or all the signatures on the certificate may be facsimile.

 

Section 7.2 - Transfers of Stock

 

Stock of the corporation shall be transferable in the manner prescribed by applicable law and in these By-laws. Transfers of stock shall be made on the books of the corporation, and in the case of certificated shares of stock, only by the person named in the certificate or by such person’s attorney lawfully constituted in writing and, except where a certificate is issued in accordance with Section 7.4 of this Article, upon the surrender of the certificate therefor, properly endorsed for transfer and payment of all necessary transfer taxes; or, in the case of uncertificated shares of stock, upon receipt of proper transfer instructions from the registered holder of the shares or by such person’s attorney lawfully constituted in writing, and upon payment of all necessary transfer taxes and compliance with appropriate procedures for transferring shares in uncertificated form; provided, however, that such surrender and endorsement, compliance or payment of taxes shall not be required in any case in which the officers of the corporation shall determine to waive such requirement. With respect to certificated shares of stock, every certificate exchanged, returned or surrendered to the corporation shall be marked “Cancelled,” with the date of cancellation, by the secretary or assistant secretary of the corporation or the transfer agent thereof. No transfer of stock shall be valid as against the corporation for any purpose until it shall have been entered in the stock records of the corporation by an entry showing from and to whom transferred.

 

10

 

 

Section 7.3 - Record Date

 

The Board of Directors may fix a record date, which shall not be more than sixty nor less than ten days before the date of any meeting of shareholders, nor more than sixty days prior to the time for the other action hereinafter described, as of which there shall be determined the shareholders who are entitled: to notice of or to vote at any meeting of shareholders or any adjournment thereof; to express consent to corporate action in writing without a meeting; to receive payment of any dividend or other distribution or allotment of any rights; or to exercise any rights with respect of any change, conversion or exchange of stock or with respect to any other lawful action.

 

Section 7.4 - Lost, Stolen or Destroyed Certificates

 

In the event of the loss, theft or destruction of any certificate of stock, another may be issued in its place pursuant to such regulations as the Board of Directors may establish concerning proof of such loss, theft or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.

 

Section 7.5 - Regulations

 

The issue, transfer, conversion and registration of certificates of stock shall be governed by such other regulations as the Board of Directors may establish.

 

ARTICLE VIII - NOTICES

 

Section 8.1 - Notices

 

Whenever notice is required to be given to any shareholder, director, officer, or agent, such requirement shall not be construed to mean personal notice. Such notice may in every instance be effectively given by depositing a writing in a post office or letter box, in a postpaid, sealed wrapper, or by dispatching a prepaid telegram, addressed to such shareholder, director, officer, or agent at his or her address as the same appears on the books of the corporation. The time when such notice is dispatched shall be the time of the giving of the notice.

 

Section 8.2 - Waivers

 

A written waiver of any notice, signed by a shareholder, director, officer or agent, whether before or after the time of the event for which notice is given, shall be deemed equivalent to the notice required to be given to such shareholder, director, officer or agent. Neither the business nor the purpose of any meeting need be specified in such a waiver.

 

ARTICLE IX - MISCELLANEOUS

 

Section 9.1 - Facsimile Signatures

 

In addition to the provisions for the use of facsimile signatures elsewhere specifically authorized in these By-laws, facsimile signatures of any officer or officers of the corporation may be used whenever and as authorized by the Board of Directors or a committee thereof.

 

Section 9.2 - Corporate Seal

 

The Board of Directors may provide a suitable seal, containing the name of the corporation, which seal shall be in the charge of the secretary. If and when so directed by the Board of Directors or a committee thereof, duplicates of the seal may be kept and used by the treasurer or by the assistant secretary or assistant treasurer.

 

11

 

 

Section 9.3 - Reliance upon Books, Reports and Records

 

Each director, each member of any committee designated by the Board of Directors, and each officer of the corporation shall, in the performance of his duties, be fully protected in relying in good faith upon the books of account or other records of the corporation, including reports made to the corporation by any of its officers, by an independent certified public accountant, or by an appraiser selected with reasonable care.

 

Section 9.4 - Fiscal Year

 

The fiscal year of the corporation shall be as fixed by resolution of the Board of Directors.

 

Section 9.5 - Time Periods

 

In applying any of these By-laws which require that an act be done or not done a specified number of days prior to any event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded and the day of the event shall be included.

 

ARTICLE X - AMENDMENTS

 

Section 10.1 - Amendments

 

These By-laws, or any portion hereof, may be amended or repealed by the Board of Directors at any meeting or by the shareholders at any meeting.

 

12

 EX-101.SCH 3 ameh-20240226.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ameh-20240226_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 5 ameh-20240226_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 26, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 26, 2024
Current Fiscal Year End Date --12-31
Entity File Number 001-37392
Entity Registrant Name ASTRANA HEALTH, INC.
Entity Central Index Key 0001083446
Entity Tax Identification Number 95-4472349
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1668 S. Garfield Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Alhambra
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91801
City Area Code 626
Local Phone Number 282-0288
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ASTH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Apollo Medical Holdings, Inc.
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apollomed.net/role/Cover Cover Cover 1 false false All Reports Book All Reports ameh-20240226.xsd ameh-20240226_lab.xml ameh-20240226_pre.xml tm247084d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm247084d1_8k.htm": { "nsprefix": "AMEH", "nsuri": "http://apollomed.net/20240226", "dts": { "schema": { "local": [ "ameh-20240226.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ameh-20240226_lab.xml" ] }, "presentationLink": { "local": [ "ameh-20240226_pre.xml" ] }, "inline": { "local": [ "tm247084d1_8k.htm" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 60, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://apollomed.net/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247084d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247084d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-027198-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-027198-xbrl.zip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�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end XML 16 tm247084d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001083446 2024-02-26 2024-02-26 iso4217:USD shares iso4217:USD shares false --12-31 0001083446 8-K 2024-02-26 ASTRANA HEALTH, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 Apollo Medical Holdings, Inc. false false false false Common Stock ASTH NASDAQ false